Back to Main

Faculty Detail    
Campus Address CHB 118
Phone  205-996-7881
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pediatrics   Ped - Infectious Disease Associate Professor
Center  Center for AIDS Research  Center for AIDS Research Associate Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Associate Professor

Graduate Biomedical Sciences Affiliations
Medical Scientist Training Program 

Biographical Sketch 
University of Alabama at Birmingham, Ph.D. in Microbiology, 1993

Society Memberships
Organization Name Position Held Org Link
American Society of Gene Therapy  Associate Member   
American Society of Virology  Associate Member   

Research/Clinical Interest
Oncolytic Virus Therapy of Malignancies

Selected Publications 
Publication PUBMEDID
Parker, S.D., Rottinghaus, S.T., Zajac, A.J., Yue, L., Hunter, E., Whitley, R.J. and Parker, J.N. (2007). HIV-189.6 Gag Expressed from a Replication Competent HSV-1 Vector Elicit Persistent Cellular Immune Responses in Mice. Vaccine. 2007 Jul 27, [Epub ahead of print]   
Shah A.C., Parker, J.N., Gillespie, G.Y., Lakeman F, Meleth, S., Markert, J.M., and Cassady, K.A. (2007). Enhanced anti-glioma activity of Chimeric HCMV/HSV 1 oncolytic viruses. Gene Therapy, 14(13): 1045-54. [Epub ahead of print 2007 Apr 12].   
Guffey, M.B., Parker, J.N., Luckett, W., Gillespie, G.Y., Meleth, S., Whitley, R.J., and Markert, J.M. (2007). Engineered Herpes Simplex Virus Expressing Bacterial Cytosine Deaminase for Experimental Therapy of Brain Tumors. Cancer Gene Therapy, 14(1):45-56. [Epub ahead of print Sept 22, 2006].   
Markert, J, Parker, J,N., Buchsbaum, DJ, Grizzle, W, Gillespie, GY and Whitley, R. (2006). Oncolytic HSV-1 for the Treatment of Brain Tumors. Herpes, 13(3):66-71.   
Shah, A.C., Price, K.H., Parker, J.N., Samuel, S., Cassady, K.A., Gillespie, G.Y., Whitley, R.J., and Markert, J.M. (2006). Human Glioma Xenograft Serial Passage Selects for a delta gamma-1 34.5 Herpes Simplex Virus Type-1 Mutant with Enhanced Anti-Tumor Activity and Decreased Neurotoxicity. J. Virol. 80: 7308-7315.   
Parker, J.N., Pfister, L.-A., Quenelle, D., Gillespie, G.Y., Markert, J.M., Kern, E.R., and Whitley, R.J. (2006). Genetically Engineered Herpes Simplex Viruses That Express IL-12 or GM-CSF as Vaccine Candidates. Vaccine, 6:24(10): 1644-52. [Epub ahead of print, Oct 5, 2005]   
Kriesel, J.D., Spruance, S.L., Pritchard, M., Parker, J.N., and Kern, E.R. (2005). Recurrent Antiviral-Resistant Genital Herpes in an Immunocompetent Patient. J. Infectious Diseases, 192:156-61.   
Hellums, E.K., Markert, J.M., Parker, J.N., He, B., Perbal, B., Roizman, B., Whitley, R.J., Langford, C.P. and Gillespie, G.Y. (2005). Increased Efficacy of an IL-12 secreting HSV in a Syngeneic Intracranial Murine Glioma Model. Neuro-Oncology, 7(3):213-24.   
Parker, J.N., Meleth, S., Hughes, K.B., Gillespie, G.Y., Whitley, R.J. and Markert, J.M. (2005). Enhanced Inhibition of Syngeneic Murine Tumors by Combinatorial Therapy with Genetically Engineered HSV-1 Expressing CCL-2 and IL-12. Cancer Gene Therapy 12:359-68.   
Markert, J.M., Parker, J.N., Gillespie, G.Y., and Whitley, R.J. (2001). “Genetically Engineered Herpes Simplex Virus in the Treatment of Brain Tumors”. Herpes. 8(1):17-22.   
Parker, J.N., Gillespie, G.Y., Love, C.E., Randall, S., Whitley, R.J. and Markert, J.M. (2000). From the cover: “Engineered Herpes Simplex Virus Expressing Interleukin 12 in the Treatment of Experimental Murine Brain Tumors.” Proceedings of the National Academy of Sciences, U.S.A. 97:2208-2213.